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See Article, pages 802–808Primary sclerosing cholangitis (PSC) mainly affects young adults
and progresses to end-stage liver disease or cholangiocarcinoma
within 15–20 years [1,2]. For these reasons most studies on the
course of PSC have concentrated upon the progression of liver
disease and the risk of malignancy. The study by Ludvigsson pre-
sented in this issue of the Journal [3] is of interest, since the
authors focused on associations with cardiovascular and other
chronic diseases that may not only affect patient health on the
long term but may also provide clues to a better understanding
of the pathogenesis of PSC. The authors should be applauded
for their efforts to dissect the hereditary component of associated
diseases from the effects of the chronic disease itself by including
around 3000 ﬁrst-degree relatives in addition to controls
obtained from the Swedish National Registry.
The aetiology of PSC remains unknown. The risk of developing
PSC in ﬁrst-degree relatives is strongly elevated and the genetic
associations of PSC have been extensively studied in recent years
[4,5]. It is clear that the HLA locus harbours a large part of the
genetic risk for PSC. Among the non-HLA genes associated with
the disease there are many risk variants in immunologically rel-
evant genes shared with several other autoimmune diseases [5].
It is therefore not surprising, that PSC is associated with other
immune-mediated and autoimmune diseases such as sarcoidosis,
thyroid disease, and rheumatoid arthritis. Also, the prevalence of
type 1 diabetes (T1D) has been reported to be highly increased in
patients with PSC [6]. The shared genetic predisposition to
develop T1D is nicely conﬁrmed in the present study, since the
prevalence of T1D, but not of the other chronic diseases analysed,
was increased in the ﬁrst-degree relatives of patients with PSC.
In order to assess novel disease associations with PSC, almost
700 PSC patients from several tertiary care centres in Sweden
were compared to more than 6000 controls obtained from the
Swedish National Registry. The authors found an increased risk
of non-ischemic cardiovascular disease (CVD) and type 2 diabetes
mellitus (T2D) in PSC patients.
While the novel associations that Ludvigsson et al. point out in
their study are interesting, several limitations of their multicentre
cohort study must be considered when interpreting the results.Journal of Hepatology 20
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Open access under CC BY-NC-ND license.The authors argue that they have evaluated a large proportion
of all PSC patients from the respective regions since for this dis-
ease patients are usually referred to tertiary care centres. The con-
trols from the general population were matched for age, sex,
calendar year, and county. Importantly though, it would appear
likely that in expert centres for a rare disease other entities will
be diagnosed with higher sensitivity when compared to the gen-
eral population with patients seen in primary or secondary care
units. Therefore, selection bias may have signiﬁcantly inﬂuenced
the results. The authors present the associations of diseases that
they have identiﬁed in groups as they are listed in the ICD-code,
and not as speciﬁc diseases. This makes it difﬁcult to delineate
possible pathophysiological concepts behind the data especially
since numerous ICD-entities within these groups are expected
to be associated with advanced liver disease in general.
What can we learn from an association of PSC with cardiovas-
cular disease and type 2 diabetes and how could these ﬁndings be
incorporated into novel pathogenetic concepts? From the clinical
point of view, we may not have screened our patients enough for
these diseases since the described associations have not come up
in single center analyses. From the scientiﬁc point of view, these
results could fuel novel pathophysiological concepts that may
help to better understand PSC pathogenesis. The association of
PSC with atherosclerosis might reﬂect the increased inﬂammatory
burden of an individual with a chronic inﬂammatory condition.
Some autoimmune rheumatic diseases have been associated with
premature atherosclerosis [7]. Still, the pathomechanism underly-
ing this association is unknown. What could be the possible
underlying pathophysiology of PSC and atherosclerosis, two dis-
eases that come along with sclerosis, dyslipidemia and evidence
of endothelial dysfunction [8]? One of the links between chronic
inﬂammation of the liver and atherosclerosis could be provided
by the effects of bile salts and their receptors as they are now rec-
ognized as important mediators of inﬂammation, endocrine func-
tion, and energy metabolism [9]. For example, polymorphisms for
the gene encoding the G-protein coupled bile acid receptor TGR5
were associated with PSC and ulcerative colitis [10] and muta-
tions found within the TGR5 gene in PSC were demonstrated to
reduce TGR5 signalling capacity [11]. Among others, TGR5 is
expressed by cholangiocytes, liver sinusoidal endothelial cells
and macrophages [12]. In Kupffer cells, bile acid induced TGR5
activation reduced LPS mediated cytokine secretion [13]. In a
mouse model the activation of this receptor in macrophages
inhibited the production of pro-inﬂammatory cytokines and14 vol. 60 j 687–688
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attenuated atherosclerosis [14]. These results suggest that an
altered function of TGR5 could represent a link between cardio-
vascular risk and bile duct pathology in patients with PSC.
The incidence of inﬂammatory bowel diseases (IBD) and also
PSC is increasing in many countries [15]. There is now accumulat-
ing evidence that dietary factors may contribute to the rising inci-
dence of IBD [16]. In IBD, there is also growing support for the
concept that the normal intestinalmicrobiota is dysbalanced. Dev-
kota et al. have recently demonstrated in a mouse model how die-
tary fats could promote a change in bile acid composition and as a
result could lead to chronic intestinal inﬂammation in a suscepti-
ble host [17,18]. Atherosclerosis was also linked to the intestinal
microbiota in another mouse model: Wang et al. showed that die-
tary phosphatidylcholine was metabolized by a gut ﬂora depen-
dent process resulting in the promotion of atherosclerosis [19].
For PSC, being closely linked to IBD, one could therefore speculate
that an altered bile acid composition or bacterial dysbalancemight
affect disease pathogenesis. The obvious questions now are:What
is the microbiome of PSC and how does it relate to the bile acid
composition in ductular bile, in the intestine and the blood? Can
weﬁndamicrobial dysbiosis or evenpathobionts that trigger com-
plications such as inﬂammation, cancer or atherosclerosis?
Should this study impact on how we evaluate our PSC
patients? Should we look for T2D and atherosclerosis more
extensively? For us the results of this study were surprising since
it is not our clinical experience that vascular disease or T2D are
relevant problems in the PSC population. Generally, we observe
health behaviour in our patients that should protect these indi-
viduals against T2D or atherosclerosis (non-smoking, normal
BMI, healthy diet). Would this imply that the patients reported
here would have been at an even higher risk for these diseases
if they behaved like the average individual? Before these novel
ﬁndings alter the clinical management of our patients the results
should clearly be conﬁrmed in other large patient cohorts.
In summary, the associations described here by Ludvigsson
et al. give stimulating input to develop ideas on the aetiology
and pathogenesis of PSC. Is PSC the atherosclerosis of the biliary
tree, as has been suggested by Fickert and colleagues [20]? The
time has come to bring together experts from the ﬁelds of meta-
bolic diseases, immunology as well as hepatology in order to
decipher the pathogenesis of PSC.Conﬂict of interest
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